(NASDAQ: VTVT) Vtv Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.67%.
Vtv Therapeutics's earnings in 2026 is -$26,974,000.On average, 7 Wall Street analysts forecast VTVT's earnings for 2026 to be -$14,036,969, with the lowest VTVT earnings forecast at -$18,488,830, and the highest VTVT earnings forecast at -$5,293,551. On average, 7 Wall Street analysts forecast VTVT's earnings for 2027 to be -$17,307,233, with the lowest VTVT earnings forecast at -$25,127,825, and the highest VTVT earnings forecast at -$13,275,233.
In 2028, VTVT is forecast to generate -$16,963,783 in earnings, with the lowest earnings forecast at -$27,250,759 and the highest earnings forecast at -$12,489,472.